Cross-Sector entity
Every one of those 2 sits in a single category, acquisition. Scemblix is most often covered alongside Keytruda, which appears in 2 of these 2 stories. We currently track 2 Cross-Sector stories that mention Scemblix, all published on March 25, 2026.
2 verified stories tracked
Last mentioned: Mar 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, acquisition. Scemblix is most often covered alongside Keytruda, which appears in 2 of these 2 stories. We currently track 2 Cross-Sector stories that mention Scemblix, all published on March 25, 2026. Each carries 2 original sources on average.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Scemblix. Shared-story counts are live from our verified record — not editorial picks.
Keytruda Patent Cliff
Merck faces the loss of exclusivity for its top-selling cancer immunotherapy.
Expected Closing
Anticipated completion of the acquisition following regulatory reviews.
Acquisition Announcement
Merck announces definitive agreement to buy Terns for $6.7 billion.
Terns Acquisition Announced
Merck agrees to buy Terns Pharmaceuticals for $6.7 billion to acquire TERN-701.
Clinical Progress
Terns Pharmaceuticals advances TERN-701 through early-stage clinical trials for CML.
Prometheus Acquisition
Merck buys Prometheus Biosciences for $10.8 billion to bolster its immunology pipeline.
Acceleron Acquisition
Merck acquires Acceleron Pharma for $11.5 billion to expand in cardiovascular disease.
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a promising allosteric BCR-ABL inhibitor for leukemia. The deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its blockbuster drug, Keytruda.
Merck has reached a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a promising Phase 2 leukemia treatment. The cash deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its blockbuster drug Keytruda.
